Clinical Trials Browser

Phase 1/2 × NIH × daratumumab × Clear all

NCT03701321 2023-09-26

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Withdrawn

Multiple Myeloma